Ontruzant

ONTRUZANT is a trastuzumab-based biologic developed by Samsung Bioepis, designed to match the structure and function of the reference trastuzumab molecule used in oncology care. It is produced using advanced biotechnology processes that ensure high similarity in quality, purity, and biological activity to the original product, meeting strict international regulatory standards.
Trastuzumab works by targeting the HER2 (human epidermal growth factor receptor 2) protein, which is overexpressed in certain types of breast and gastric cancers. By binding to this receptor, trastuzumab interferes with cancer cell growth and division, while also activating immune system mechanisms that help the body recognize and destroy abnormal cells. ONTRUZANT follows this same scientific principle, offering a comparable biological action and therapeutic effect.
The development of ONTRUZANT reflects the growing role of biosimilars in modern healthcare. Biosimilars are highly similar versions of existing biologic therapies, created to expand access to advanced treatments while maintaining rigorous safety, quality, and efficacy standards. Extensive analytical testing, clinical evaluation, and comparative studies support ONTRUZANT’s similarity to reference trastuzumab in terms of structure, function, and clinical performance.
Samsung Bioepis focuses on innovation, large-scale biologic manufacturing, and global accessibility. Through products like ONTRUZANT, the company contributes to broader availability of complex biologic therapies across multiple healthcare systems. This approach supports sustainability in healthcare by encouraging competition, improving affordability, and increasing patient access to advanced biologic treatments worldwide.